Development of an Ad7 cosmid system and generation of an Ad7ΔE1ΔE3HIVMN env/rev recombinant virus

被引:18
作者
Nan, X
Peng, B
Hahn, TW
Richardson, E
Lizonova, A
Kovesdi, I
Robert-Guroff, M
机构
[1] NCI, Basic Res Lab, Bethesda, MD 20892 USA
[2] GenVec, Gaithersburg, MD USA
关键词
Ad7; recombinants; HIV; cosmid system;
D O I
10.1038/sj.gt.3301903
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A strategy to circumvent immune responses to adenovirus (Ad) resulting from natural infection or repeated vector administrations involves sequential use of vectors from different Ad serotypes. To further develop an Ad-HIV recombinant AIDS vaccine approach, a replication-defective recombinant Ad from a non-subgroup C virus was required. Using a cosmid system, we generated an AdDeltaE1JDeltaE3HI(MN) env/rev recombinant virus and compared expression of the inserted HIV genes with a similarly constructed replication-competent Ad7DeltaE1DeltaE3HIV(MN)env/rev recombinant. Ad7DeltaE1DeltaE3HIV(MN)env/rev expressed both HIV env and rev gene products. The envelope protein was correctly processed and functional, mediating syncytia formation of Ad7DeltaE1DeltaE3HIV(MN) env/rev-infected cells and CD4(+) T lymphocytes. AdDeltaE1DeltaE3H1V(MN)env/rev could be amplified on 293-ORF6 cells, containing the E4 ORF6 gene, shown earlier to support production of an Ad7 vector lacking the E1a gene. The utility of this cell line is now extended to the production of replication-defective Ad7 recombinants lacking E1a, E1b, and protein IX genes. Sequential immunizations with Ad-HIV recombinants based in different Ad serotypes have been shown to effectively elicit both humoral and cellular HIV-specific immune responses. The recombinant Ad7DeltaE1DeltaE3HlV(MN)env/rev will be useful in such AIDS vaccine strategies. Further, these studies have created new cosmid vectors that can be applied to generation of single- or double-deleted Ad7 recombinants with foreign genes inserted into the El and/or E3 regions.
引用
收藏
页码:326 / 336
页数:11
相关论文
共 65 条
[1]   Construction of an adenovirus type 7a E1A(-) vector [J].
Abrahamsen, K ;
Kong, HL ;
Mastrangeli, A ;
Brough, D ;
Lizonova, A ;
Crystal, RG ;
FalckPedersen, E .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8946-8951
[2]  
[Anonymous], 1989, SYNTHETIC OLIGONUCLE
[3]   PROTECTIVE IMMUNITY TO ROTAVIRUS-INDUCED DIARRHEA IS PASSIVELY TRANSFERRED TO NEWBORN MICE FROM NAIVE DAMS VACCINATED WITH A SINGLE DOSE OF A RECOMBINANT ADENOVIRUS EXPRESSING ROTAVIRUS VP7SC [J].
BOTH, GW ;
LOCKETT, LJ ;
JANARDHANA, V ;
EDWARDS, SJ ;
BELLAMY, AR ;
GRAHAM, FL ;
PREVEC, L ;
ANDREW, ME .
VIROLOGY, 1993, 193 (02) :940-950
[4]   THE USE OF ADENOVIRAL VECTORS FOR GENE-THERAPY AND GENE-TRANSFER IN-VIVO [J].
BRAMSON, JL ;
GRAHAM, FL ;
GAULDIE, J .
CURRENT OPINION IN BIOTECHNOLOGY, 1995, 6 (05) :590-595
[5]   A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4 [J].
Brough, DE ;
Lizonova, A ;
Hsu, C ;
Kulesa, VA ;
Kovesdi, I .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6497-6501
[6]   An adenovirus simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge [J].
Buge, SL ;
Richardson, E ;
Alipanah, S ;
Markham, P ;
Cheng, S ;
Kalyan, N ;
Miller, CJ ;
Lubeck, M ;
Udem, S ;
Eldridge, J ;
RobertGuroff, M .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8531-8541
[7]   Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251 (vol 73, pg 7430, 1999) [J].
Buge, SL ;
Murty, L ;
Arora, K ;
Kalyanaraman, VS ;
Markham, PD ;
Richardson, ES ;
Aldrich, K ;
Patterson, LJ ;
Miller, CJ ;
Cheng, SM ;
Robert-Guroff, M .
JOURNAL OF VIROLOGY, 1999, 73 (11) :9692-9692
[8]   HUMAN ADENOVIRUS TYPE-5 RECOMBINANTS EXPRESSING SIMIAN IMMUNODEFICIENCY VIRUS MACAQUE STRAIN GAG ANTIGENS [J].
CARAVOKYRI, C ;
PRINGLE, CR ;
LEPPARD, KN .
JOURNAL OF GENERAL VIROLOGY, 1993, 74 :2819-2824
[9]   HIGH-LEVEL EXPRESSION OF THE ENVELOPE GLYCOPROTEINS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN PRESENCE OF REV GENE USING HELPER-INDEPENDENT ADENOVIRUS TYPE-7 RECOMBINANTS [J].
CHANDA, PK ;
NATUK, RJ ;
MASON, BB ;
BHAT, BM ;
GREENBERG, L ;
DHEER, SK ;
MOLNARKIMBER, KL ;
MIZUTANI, S ;
LUBECK, MD ;
DAVIS, AR ;
HUNG, PP .
VIROLOGY, 1990, 175 (02) :535-547
[10]   EVALUATION OF ADENOVIRUS TYPE-4 AND TYPE-7 RECOMBINANT HEPATITIS-B VACCINES IN DOGS [J].
CHENGALVALA, M ;
LUBECK, MD ;
DAVIS, AR ;
MIZUTANI, S ;
MOLNARKIMBER, K ;
MORIN, J ;
HUNG, PP .
VACCINE, 1991, 9 (07) :485-490